Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Verteporfin Blocks Growth of Deadly Eye Melanoma

By BiotechDaily International staff writers
Posted on 08 Jun 2014
Print article
Image: An untreated uveal melanoma tumor (left) covers entire eye of a mouse. A tumor treated with verteporfin (right) is much smaller and much of the structure of the mouse\'s eye is visible (Photo courtesy of UCSD - University of California, San Diego).
Image: An untreated uveal melanoma tumor (left) covers entire eye of a mouse. A tumor treated with verteporfin (right) is much smaller and much of the structure of the mouse\'s eye is visible (Photo courtesy of UCSD - University of California, San Diego).
Simultaneous mutations in two G-protein encoding genes that cause the overexpression of a carcinogenic protein have been linked to the development of uveal melanoma, a deadly cancer of the colored areas of the eye.

Uveal melanoma is a rare cancer that is usually treated by surgical removal of the eye. However, uveal melanoma can spread to the liver, in which case patients typically die within two to eight months after diagnosis.

Genome studies have shown that a mutation in either the GNAQ (guanine nucleotide binding protein, q polypeptide) or GNA11 (guanine nucleotide-binding protein subunit alpha-11) genes, which encode the proteins Gq or G11, respectively, are found in about 70% of uveal melanoma tumors.

In the current study, which was published in the May 29, 2014, online edition of the journal Cancer Cell, investigators at the University of California, San Diego (USA) revealed that that these mutations cause the G-proteins to become permanently activated, which results in overexpression of the Yes-associated protein (YAP). Overexpression of YAP protein induces uncontrolled cell growth and inhibits cell death, triggering cancer development. Furthermore, treatment of uveal melanoma tumors with the YAP inhibitor drug verteporfin blocked tumor growth of cells containing Gq/G11 mutations.

“The beauty of our study is its simplicity,” said senior author Dr. Kun-Liang Guan, professor of pharmacology at the University of California, San Diego. “The genetics of this cancer are very simple and our results have clear implications for therapeutic treatments for the disease. We have a cancer that is caused by a very simple genetic mechanism, and we have a drug that works on this mechanism. The clinical applications are very direct.”

Related Links:

University of California, San Diego



Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A 3D nanofiber net formed by the supergelators to trap oil molecules (Photo courtesy of IBN at A*STAR / Institute of Bioengineering and Nanotechnology).

Effective Cleanup with Smart Material That Forms Oil-Trapping Net

Researchers have developed supergelators – an organic oil-scavenging material that rapidly forms a 3D net to trap oil molecules, gelatinizing into solidified masses that can be more easily removed from... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.